ID: ALA222305

Max Phase: Preclinical

Molecular Formula: C13H16N2O5

Molecular Weight: 280.28

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC#Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C13H16N2O5/c1-2-3-4-8-6-15(13(19)14-12(8)18)11-5-9(17)10(7-16)20-11/h6,9-11,16-17H,2,5,7H2,1H3,(H,14,18,19)/t9-,10+,11+/m0/s1

Standard InChI Key:  PXCHYHBELCFZQQ-HBNTYKKESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 280.28

Molecular Weight (Monoisotopic): 280.1059

AlogP: -1.06

#Rotatable Bonds: 2

Polar Surface Area: 104.55

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.44

CX Basic pKa:

CX LogP: -0.20

CX LogD: -0.20

Aromatic Rings: 1

Heavy Atoms: 20

QED Weighted: 0.60

Np Likeness Score: 0.92

References

1. Goodchild J, Porter RA, Raper RH, Sim IS, Upton RM, Viney J, Wadsworth HJ..  (1983)  Structural requirements of olefinic 5-substituted deoxyuridines for antiherpes activity.,  26  (9): [PMID:6887201] [10.1021/jm00363a009]

2. De Clercq E, Descamps J, Balzarini J, Giziewicz J, Barr PJ, Robins MJ..  (1983)  Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides.,  26  (5): [PMID:6302254] [10.1021/jm00359a008]

3. Helguera AM, Rodríguez-Borges JE, García-Mera X, Fernández F, Cordeiro MN..  (2007)  Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.,  50  (7): [PMID:17341060] [10.1021/jm061445m]

Source

Source(1):

• Scientific Literature